KC-3259

LU99-MTAP Cell Line

×
26477
Home » Cell Lines » LU99-MTAP Cell Line

Background of LU99-MTAP Cell Line

Methylthioadenosine phosphorylase (MTAP), also known as MSAP, is an enzyme that recycles adenine and methionine after polyamine synthesis. Human MTAP is expressed across many tissues, including epithelial organs, rather than being lung-specific. Homozygous deletion at chromosome 9p21 often accompanies CDKN2A loss in cancers such as lung tumors, mesothelioma and glioma. MTAP loss can increase methylthioadenosine and create vulnerability to inhibition of protein arginine methyltransferase 5 (PRMT5) or methionine adenosyltransferase 2A (MAT2A). This biology has prompted development of biomarker-selected therapies. MRTX1719, also called BMS-986504, is an investigational MTA-cooperative PRMT5 inhibitor with preclinical activity and early clinical responses reported in some MTAP-deleted cancers. These studies concern MTAP-deficient tumors and do not establish clinical efficacy for an MTAP-expressing cell line.

Specifications

Catalog NumberKC-3259
Cell Line NameLU99-MTAP Cell Line
NCBI/UniProt Accession NumberNM_002451.4
Clone Number1#
Host Cell LineLU99
DescriptionLU99 cell line stably expressing exogenous human MTAP gene
QuantityOne vial of frozen cells (≥2×106 cells)
StabilityStable in culture over a minimum of 10 passages
ApplicationDrug screening and biological assays
Freezing Medium70% RPMI1640+20% FBS+10% DMSO
Propagation MediumRPMI1640+10%FBS+1 μg/mL Puromycin
Selection MarkerPuromycin
MorphologyEpithelial-like
SubcultureSplit at a ratio of 1:10 every 3 days
Incubation37 °C with 5% CO₂
StorageLiquid nitrogen immediately upon receiving
Doubling TimeEstimated 21–25 hours
Mycoplasma StatusNegative
In Vivo ValidationNA

Cell Line Generation

LU99-MTAP cell line was generated through lentiviral transduction to stably express the human MTAP sequence.

Characterization

Figure 1: Characterization of MTAP expression in LU99 and the LU99-MTAP stable clone (1#) using Western blot.

Figure 2: Characterization of LU99-MTAP stable clone (1#) response to MRTX-1719 following 8-day treatment, based on the percentage of surviving cells.

Cell Resuscitation

  1. Pre-warm complete culture medium (basal medium and 10% FBS) in a 37°C water bath.
  2. Rapidly thaw the cryovial in a 37°C water bath for 1-2 minutes with gentle agitation.
  3. Transfer the vial to a biosafety cabinet, and disinfect the exterior with 70% ethanol.
  4. Aseptically transfer the cell suspension dropwise into a sterile centrifuge tube containing 9.0 mL of pre-warmed complete medium.
  5. Centrifuge at approximately 125 × g for 5–7 minutes at room temperature, carefully aspirate the supernatant without disturbing the cell pellet.
  6. Gently resuspend the pellet in an appropriate volume of complete medium and transfer the suspension into a T25 flask.
  7. Incubate the flask in a 37°C in a humidified 5% CO₂ incubator.
  8. Assess cell viability and morphology after 24 hours. If cells appear healthy, replace the medium with fresh medium supplemented with the appropriate selective antibiotic.
  9. Subculture the cells at a ratio of 1:10 every 3 days upon reaching 80%–90% confluency.

Cell Freezing

  1. Prepare the freezing medium (70% basal medium, 20% FBS and 10% DMSO) freshly before use.
  2. Pre-chill the freezing medium on ice and label the cryovials accordingly.
  3. Transfer the cell suspension to a sterile conical tube and perform a cell count to determine total viability and density.
  4. Centrifuge the cells at 250×g for 5 minutes at room temperature; carefully aspirate the supernatant.
  5. Gently resuspend the pellet in chilled freezing medium, ensuring a minimum cell density of 3×10⁶ cells/mL.
  6. Aliquot 1 mL of the cell suspension into each pre-labeled cryovial.
  7. Place the cryovials into a CoolCell® container and store at -80°C overnight for controlled-rate cooling.
  8. Transfer the cryovials to the liquid nitrogen for long-term storage the following day.

References

  1. Smith CR et al. Fragment-Based Discovery of MRTX1719, a Synthetic Lethal Inhibitor of the PRMT5–MTA Complex for the Treatment of MTAP-Deleted Cancers. J Med Chem. 2022;65(3):1749–1766. doi:10.1021/acs.jmedchem.1c01900.
  2. Engstrom LD et al. MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with MTAP-Deleted Cancer. Cancer Discov. 2023;13(11):2412–2431. doi:10.1158/2159-8290.CD-23-0669.
  3. Ngoi NYL et al. Methylthioadenosine Phosphorylase Genomic Loss in Advanced Gastrointestinal Cancers. Oncologist. 2024;29(6):493–503. doi:10.1093/oncolo/oyae011.

Use License Agreement

Research Use Only.
Not for use in diagnostic procedures or therapeutic applications.
Redistribution of the cell line or its derivatives is prohibited without prior written permission from Kyinno Biotechnology.